EndoGastric Solutions, a Redmond, Wash.-based leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), secured $30.5m in financing.
The round was led by existing investors Advanced Technology Ventures (ATV), Canaan Partners, Canepa Healthcare, Chicago Growth Partners, CRG, Radius Ventures, Sightline Partners, and several new investors.
The company intends to use the funds to continue its commercial expansion of the TIF® procedure in support of its physician customer base, while continuing to invest in sustaining engineering to optimize gross margin.
Led by Skip Baldino, President and CEO, EndoGastric Solutions is a medical device company developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of Gastroesophageal reflux disease (GERD).
GERD is a chronic condition in which the gastroesophageal valve (GEV) allows gastric contents to reflux (wash backwards) into the esophagus, causing heartburn and possible injury to the esophageal lining.